ABEONA THERAPEUTICS INC. Retained Earnings
ABEONA THERAPEUTICS INC. (ABEO) had Retained Earnings of -$779.34 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-13
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$779.34M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$759.15M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$742.08M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$721.62M.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-06-30 | -$779.34M 10-Q · filed 2026-08-13 | |
| 2026-03-31 | -$759.15M 10-Q · filed 2026-05-13 | |
| 2025-12-31 | -$742.08M 10-Q · filed 2026-08-13 | |
| 2025-09-30 | -$721.62M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | -$716.45M 10-Q · filed 2025-08-14 | |
| 2025-03-31 | -$825.29M 10-Q · filed 2025-05-15 | |
| 2024-12-31 | -$813.26M 10-K · filed 2026-03-17 | |
| 2024-09-30 | -$803.97M 10-Q · filed 2024-11-14 | |
| 2024-06-30 | -$773.70M 10-Q · filed 2024-08-12 | |
| 2024-03-31 | -$781.10M 10-Q · filed 2024-05-15 | |
| 2023-12-31 | -$749.52M 10-K · filed 2025-03-20 | |
| 2023-09-30 | -$732.93M 10-Q · filed 2023-11-13 | |
| 2023-06-30 | -$721.10M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | -$704.44M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | -$695.34M 10-K · filed 2024-03-18 | |
| 2022-09-30 | $688.22M 10-Q · filed 2023-11-13 | -$694.21M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $681.78M 10-Q · filed 2023-11-13 | -$684.73M 10-Q · filed 2022-08-11 |
| 2022-03-31 | -$676.43M 10-Q · filed 2022-05-13 | |
| 2021-12-31 | -$655.64M 10-K · filed 2023-03-29 | |
| 2021-09-30 | -$608.96M 10-Q · filed 2021-11-15 | |
| 2021-06-30 | -$601.91M 10-Q · filed 2021-07-28 | |
| 2021-03-31 | -$586.71M 10-Q · filed 2021-05-17 | |
| 2020-12-31 | -$570.70M 10-K · filed 2022-03-31 | |
| 2020-09-30 | -$554.88M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | -$547.64M 10-Q · filed 2020-08-10 | |
| 2020-03-31 | -$534.63M 10-Q · filed 2020-05-06 | |
| 2019-12-31 | -$486.47M 10-K · filed 2021-03-24 | |
| 2019-09-30 | -$470.04M 10-Q · filed 2019-11-12 | |
| 2019-06-30 | -$452.67M 10-Q · filed 2019-08-09 | |
| 2019-03-31 | -$428.74M 10-Q · filed 2019-05-10 | |
| 2018-12-31 | -$410.19M 10-K · filed 2020-03-16 | |
| 2018-09-30 | -$392.71M 10-Q · filed 2018-11-09 | |
| 2018-06-30 | -$376.29M 10-Q · filed 2018-08-09 | |
| 2018-03-31 | -$364.59M 10-Q · filed 2018-05-10 | |
| 2018-01-02 | $2.60M 10-K · filed 2020-03-16 | -$356.13M 10-Q · filed 2018-05-10 |
| 2018-01-01 | -$353.52M 10-K · filed 2019-03-18 | |
| 2017-12-31 | -$359.79M 10-K · filed 2019-03-18 | |
| 2017-09-30 | -$351.34M 10-Q · filed 2017-11-14 | |
| 2017-06-30 | -$346.00M 10-Q · filed 2017-08-14 | |
| 2017-03-31 | -$337.72M 10-Q · filed 2017-05-15 | |
| 2016-12-31 | -$332.47M 10-K · filed 2018-03-16 | |
| 2016-09-30 | -$325.47M 10-Q · filed 2016-11-14 | |
| 2016-06-30 | -$322.85M 10-Q · filed 2016-08-15 | |
| 2016-03-31 | -$316.14M 10-Q · filed 2016-05-16 | |
| 2015-12-31 | -$310.60M 10-K · filed 2017-03-30 | |
| 2015-09-30 | -$308.26M 10-Q · filed 2015-11-16 | |
| 2015-06-30 | -$302.19M 10-Q · filed 2015-08-14 | |
| 2015-03-31 | -$298.07M 10-Q · filed 2015-05-14 | |
| 2014-12-31 | -$296.07M 10-K · filed 2016-03-30 | |
| 2014-09-30 | -$283.45M 10-Q · filed 2014-11-14 | |
| 2014-06-30 | -$281.24M 10-Q · filed 2014-08-14 | |
| 2014-03-31 | -$267.27M 10-Q · filed 2014-05-12 | |
| 2013-12-31 | -$266.42M 10-K · filed 2015-03-31 | |
| 2013-09-30 | -$264.65M 10-Q · filed 2013-11-14 | |
| 2013-06-30 | -$263.75M 10-Q · filed 2013-08-14 | |
| 2013-03-31 | -$264.62M 10-Q · filed 2013-05-15 | |
| 2012-12-31 | -$267.97M 10-K · filed 2014-03-26 | |
| 2012-09-30 | -$287.12M 10-Q · filed 2012-11-14 | |
| 2012-06-30 | -$271.81M 10-Q · filed 2012-08-14 | |
| 2012-03-31 | -$260.77M 10-Q · filed 2012-05-15 | |
| 2011-12-31 | -$255.44M 10-K · filed 2013-03-20 | |
| 2010-12-31 | -$251.13M 10-K · filed 2012-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |